A carregar...
QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
OBJECTIVE: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m(2)) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment...
Na minha lista:
| Publicado no: | Eur J Breast Health |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Turkish Federation of Breast Diseases Associations
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6170019/ https://ncbi.nlm.nih.gov/pubmed/30288492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/ejbh.2018.4174 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|